Table of Contents

• The Concomitant Use of Angiotensin System Inhibitors Predicts Favorable Prognosis for Renal Cell Carcinoma Patients

  Shuenqin Hu, Xiuying Li

  Previous data suggest that Angiotensin system inhibitors (ASIs) may exert antitumor effects; however, the findings remain controversial. Therefore, the present study was conducted to evaluate the association between concomitant use of ASIs and survival outcomes in patients with renal cell carcinoma (RCC)....

  REVIEW | Published: 28 Aug 2025

  Annals of Urologic Oncology, Articles, Online First

  Full Text   PDF(1020KB)   Views：20Downloads：1

• Metabolic Reprogramming in Kidney Cancer: Implications for Therapy

  Elena Tena Edo

  Kidney cancer, particularly clear cell renal cell carcinoma (ccRCC), has emerged as a paradigm for cancer metabolic reprogramming, exhibiting distinctive alterations that drive tumor progression and therapeutic resistance. This comprehensive review synthesizes current knowledge of the molecular mechanisms underlying metabolic dysregulation in kidney cancer, with emphasis on the central role of VHL...

  REVIEW | Published: 07 Aug 2025

  Annals of Urologic Oncology, Articles, Online First

  Full Text   PDF(1290KB)   Views：289Downloads：1

• The Urological Subtleties of an Uncommon Encounter with Primary Mucinous Adenocarcinoma of the Urinary Bladder with Review of Literature

  Anuradha Pandit, Shaivy Malik ... Charanjeet Ahluwalia

  Primary mucinous adenocarcinoma (PMA) of the urinary bladder is a rare and aggressive neoplasm, accounting for 0.5-2% of bladder malignancies. We report a case of a 52-year-old male presenting with urinary obstructive symptoms and hematuria. Imaging revealed a bladder mass, and histopathology confirmed muscle-invasive mucinous adenocarcinoma with characteristic mucin pools and signet ring cells. I...

  CASE REPORT | Published: 07 Aug 2025

  Annals of Urologic Oncology, Articles, Online First

  Full Text   PDF(1810KB)   Views：211Downloads：2

• Saliva-Based Polygenic Risk Scores and AI-Enhanced Imaging for Prostate Cancer Screening beyond PSA

  Fan Li, Xian Zhang

  Prostate-specific antigen (PSA) testing, long used for prostate cancer screening, is limited by poor specificity (~25%), leading to unnecessary biopsies in over 70% of cases and substantial healthcare costs. This review synthesizes recent evidence (2023–2025) on emerging non-invasive diagnostics—saliva-based polygenic risk scores (PRS) and artificial intelligence (AI)-enhanced ...

  REVIEW | Published: 31 Jul 2025

  Annals of Urologic Oncology, Articles, Online First

  Full Text   PDF(629KB)   Views：638Downloads：2

• Synthetic Lethality in Prostate Cancer: Evaluating the Role of PARP Inhibitors in BRCA-Mutated mCRPC

  Xinliang Xu, Minna Liu

  Prostate cancer, a leading cause of cancer-related mortality in men, often progresses to metastatic castration-resistant prostate cancer (mCRPC) despite advances in treatment with androgen-receptor pathway inhibitors (ARPIs) and taxanes. Recent genomic studies have highlighted that alterations in DNA damage repair genes, notably BRCA1 and BRCA2, play a significant role in the progression of prosta...

  REVIEW | Published: 23 Jul 2025

  Annals of Urologic Oncology, Articles, Online First

  Full Text   PDF(1310KB)   Views：671Downloads：5